Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 6 | 2021 | 356 | 2.820 |
Why?
|
| Consensus | 7 | 2020 | 211 | 2.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2022 | 212 | 2.370 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 940 | 2.200 |
Why?
|
| Atrial Fibrillation | 4 | 2022 | 249 | 2.010 |
Why?
|
| Dyslipidemias | 3 | 2021 | 98 | 1.880 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2018 | 35 | 1.860 |
Why?
|
| Hemorrhage | 5 | 2020 | 328 | 1.830 |
Why?
|
| Cardiology | 3 | 2020 | 140 | 1.780 |
Why?
|
| Radiation Exposure | 3 | 2018 | 84 | 1.730 |
Why?
|
| Radiation Dosage | 3 | 2018 | 419 | 1.550 |
Why?
|
| Hypolipidemic Agents | 3 | 2021 | 82 | 1.350 |
Why?
|
| Drug Interactions | 6 | 2022 | 289 | 1.290 |
Why?
|
| Advisory Committees | 2 | 2018 | 73 | 1.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 511 | 1.150 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 82 | 0.790 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 109 | 0.730 |
Why?
|
| Societies, Medical | 2 | 2020 | 403 | 0.730 |
Why?
|
| Lipids | 1 | 2021 | 298 | 0.700 |
Why?
|
| Body Weight | 1 | 2021 | 554 | 0.650 |
Why?
|
| Research Report | 1 | 2018 | 35 | 0.640 |
Why?
|
| Tobacco Use Cessation | 1 | 2018 | 44 | 0.630 |
Why?
|
| Risk Factors | 8 | 2022 | 5731 | 0.630 |
Why?
|
| Venous Thrombosis | 2 | 2017 | 125 | 0.620 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 49 | 0.600 |
Why?
|
| Occupational Exposure | 1 | 2018 | 122 | 0.590 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 86 | 0.590 |
Why?
|
| HIV | 1 | 2017 | 56 | 0.590 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 53 | 0.580 |
Why?
|
| Gemfibrozil | 1 | 2016 | 4 | 0.540 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2007 | 178 | 0.540 |
Why?
|
| Heparin | 1 | 2017 | 205 | 0.530 |
Why?
|
| Phenytoin | 1 | 2016 | 27 | 0.530 |
Why?
|
| Dabigatran | 1 | 2016 | 35 | 0.530 |
Why?
|
| American Heart Association | 1 | 2016 | 142 | 0.530 |
Why?
|
| Disease Management | 1 | 2017 | 248 | 0.530 |
Why?
|
| Antithrombins | 1 | 2016 | 32 | 0.530 |
Why?
|
| Humans | 29 | 2022 | 68618 | 0.520 |
Why?
|
| Evidence-Based Medicine | 4 | 2018 | 438 | 0.500 |
Why?
|
| Decision Making | 1 | 2017 | 410 | 0.470 |
Why?
|
| Anticonvulsants | 1 | 2016 | 223 | 0.470 |
Why?
|
| Benchmarking | 3 | 2018 | 91 | 0.460 |
Why?
|
| Seizures | 1 | 2016 | 279 | 0.450 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 253 | 0.440 |
Why?
|
| Pharmaceutical Services | 1 | 2013 | 47 | 0.420 |
Why?
|
| Models, Organizational | 1 | 2013 | 97 | 0.420 |
Why?
|
| Patient Safety | 3 | 2018 | 202 | 0.410 |
Why?
|
| United States | 7 | 2020 | 7367 | 0.400 |
Why?
|
| Risk Assessment | 4 | 2018 | 2007 | 0.390 |
Why?
|
| Patient Discharge | 1 | 2013 | 294 | 0.370 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1465 | 0.360 |
Why?
|
| Cholesterol, LDL | 2 | 2022 | 161 | 0.350 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 425 | 0.350 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2020 | 41 | 0.350 |
Why?
|
| HIV Infections | 1 | 2017 | 791 | 0.340 |
Why?
|
| Obesity | 1 | 2017 | 1076 | 0.340 |
Why?
|
| Treatment Outcome | 5 | 2021 | 7029 | 0.310 |
Why?
|
| Heart Failure | 3 | 2013 | 1180 | 0.310 |
Why?
|
| Administration, Oral | 2 | 2020 | 411 | 0.310 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 807 | 0.300 |
Why?
|
| Acute Coronary Syndrome | 1 | 2007 | 195 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 772 | 0.220 |
Why?
|
| Hirudins | 1 | 2002 | 32 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 22 | 0.210 |
Why?
|
| Colchicine | 1 | 2022 | 48 | 0.210 |
Why?
|
| Thrombin | 1 | 2002 | 117 | 0.200 |
Why?
|
| Muscles | 1 | 2022 | 158 | 0.200 |
Why?
|
| Thrombosis | 1 | 2002 | 218 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2020 | 21 | 0.180 |
Why?
|
| Dietary Supplements | 2 | 2020 | 332 | 0.180 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 742 | 0.180 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2020 | 9 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2002 | 483 | 0.170 |
Why?
|
| Nonprescription Drugs | 1 | 2020 | 28 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2020 | 71 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2018 | 47 | 0.160 |
Why?
|
| Cholesterol | 1 | 2019 | 331 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 90 | 0.150 |
Why?
|
| Partial Thromboplastin Time | 1 | 2017 | 57 | 0.140 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2007 | 80 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.140 |
Why?
|
| Polypharmacy | 1 | 2016 | 31 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 334 | 0.140 |
Why?
|
| Risk | 1 | 2017 | 563 | 0.130 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2016 | 107 | 0.130 |
Why?
|
| Overweight | 1 | 2017 | 186 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 304 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2007 | 373 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2002 | 1615 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 291 | 0.120 |
Why?
|
| Fibrinolytic Agents | 2 | 2007 | 377 | 0.110 |
Why?
|
| Medication Reconciliation | 1 | 2013 | 18 | 0.110 |
Why?
|
| Societies, Pharmaceutical | 1 | 2013 | 22 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 1426 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 148 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2017 | 2358 | 0.090 |
Why?
|
| Middle Aged | 3 | 2020 | 21147 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2013 | 267 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 335 | 0.090 |
Why?
|
| Time Factors | 1 | 2017 | 4655 | 0.080 |
Why?
|
| Infusions, Intraosseous | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2007 | 72 | 0.070 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2006 | 22 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 189 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2006 | 41 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2006 | 71 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2006 | 113 | 0.070 |
Why?
|
| Animals | 2 | 2021 | 20881 | 0.060 |
Why?
|
| Aged | 2 | 2020 | 14862 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2017 | 7277 | 0.060 |
Why?
|
| Stents | 1 | 2007 | 657 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 122 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 931 | 0.040 |
Why?
|
| Male | 2 | 2020 | 37321 | 0.040 |
Why?
|
| Pharmacists | 2 | 2006 | 125 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2009 | 12 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2009 | 12 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 7 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 21403 | 0.020 |
Why?
|
| Professional Role | 1 | 2006 | 80 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 238 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 141 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2007 | 225 | 0.020 |
Why?
|
| Pyridines | 1 | 2006 | 261 | 0.020 |
Why?
|
| Systole | 1 | 2004 | 149 | 0.010 |
Why?
|
| Health Personnel | 1 | 2006 | 286 | 0.010 |
Why?
|
| Female | 1 | 2020 | 38074 | 0.010 |
Why?
|
| Child | 1 | 2007 | 6405 | 0.010 |
Why?
|